Burzynski Research Institute

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Burzynski Research Institute sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials none currently recruiting 13 completed early-phase tilt top decile by trial count

Burzynski Research Institute: 52 sponsored US clinical trials, none currently recruiting.

Burzynski Research Institute sponsors 52 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 0 of these trials are in Phase 3-4 (later-stage) and 52 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma Multiforme of the Brain, with 1 trials.

Top-decile sponsor footprint

Burzynski Research Institute ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

13 of 52 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (25.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

52 total, page 1 of 2

TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

NCT02988726
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Meningioma

NCT00003483
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Non-Hodgkin's Lymphoma

NCT00003498
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine

NCT00003522
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

NCT00003513
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors

NCT00003515
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stomach Cancer

NCT00003524
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Brain Tumors

NCT00003458
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT00003497
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

NCT00003453
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Brain Tumors

NCT00003457
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Low-Grade Astrocytoma

NCT00003468
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Soft Tissue Sarcoma

NCT00003521
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Cancer of the Cervix and/or Vulva

NCT00003525
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Visual Pathway Glioma

NCT00003477
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus

NCT00003487
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer

NCT00003489
TERMINATED Phase 2

Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

NCT00003452
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

NCT00003472
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma

NCT00003501
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer

NCT00003485
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003492
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer

NCT00003531
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Multiple Myeloma

NCT00003511
COMPLETED Phase 2

Antineoplaston Therapy in Treating Children With Primitive Neuroectodermal Tumors

NCT00003460
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer

NCT00003520
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

NCT00003495
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

NCT00003516
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Melanoma

NCT00003509
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer

NCT00003494
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003491
TERMINATED Phase 2

Antineoplaston Therapy in Treating Women With Stage IV Breast Cancer

NCT00003454
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin

NCT00003526
COMPLETED Phase 2

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

NCT00003474
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma

NCT00003500
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

NCT00003508
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Extensive-Stage Small Cell Lung Cancer

NCT00003496
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

NCT00003499
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

NCT00003532
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

NCT00003470
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas

NCT00003473
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Brain Stem Glioma

NCT00003459
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

NCT00003471
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

NCT00003476
TERMINATED Phase 2

Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00003533
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors

NCT00003475
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Rhabdoid Tumor of the Central Nervous System

NCT00003469
COMPLETED Phase 2

Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma

NCT00003537
COMPLETED Phase 2

Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme

NCT00003456
TERMINATED Phase 2

Antineoplaston Therapy in Treating Children With Recurrent or Refractory High-Grade Glioma

NCT00003535
Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 2 52

Therapeutic Areas

Glioblastoma Multiforme of the Brain 1
Refractory Brain Tumors 1
Adult Brain Tumor 1

How the Burzynski Research Institute early-phase archive is shaped

52 indexed studies, none listed as recruiting (0% open); 13 completed (25%).

Phase mix: 0 late (III/IV) vs 52 early (I/II) (early-phase heavy).

Top condition: Glioblastoma Multiforme of the Brain (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Burzynski Research Institute: archived-pipeline peers nationwide

Peers matched on 52 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0204060 0%5%10%15% Total trials Recruiting share Burzynski Research InstituteAlbany Medical CollegeDr. Reddy's Laboratories LimitedPTC TherapeuticsSpectrum Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Burzynski Research Institute sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Burzynski Research Institute page

52 registered trials is a research-attention snapshot, not an endorsement of Burzynski Research Institute or any single study.

  • None of Burzynski Research Institute's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Glioblastoma Multiforme of the Brain is the condition Burzynski Research Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma Multiforme of the Brain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Burzynski Research Institute pipeline card: 52 registered trials from official public datasets.Report a data error.